Nasdaq:US$20.09 (-0.08) | HKEX:HK$31.40 (-0.65) | AIM:£3.24 (+0)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.